A Pilot Study of Blood-Based Biomarkers for Response to Immune Checkpoint Inhibitors
Latest Information Update: 08 Oct 2026
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 30 Sep 2026 Planned End Date changed from 31 Jul 2026 to 31 Jul 2027.
- 30 Sep 2026 Planned primary completion date changed from 31 Jul 2026 to 31 Jul 2027.
- 10 Nov 2025 Status changed from recruiting to active, no longer recruiting.